Strategic Narrative: Partnership or Independence

Meridian Physical Therapy Group — Positioning for the Next Chapter

Date: 2026-05-30 · Prepared by: Resolvix · Status: Sample Deliverable
Deliverable type: Strategy & Business Planning — Strategic Narrative Deck (~$750)
Industry: Multi-Location Physical Therapy / Healthcare Services

About this sample. This is one example of what a successful Resolvix deliverable looks like at this scope and type — not a template that every engagement follows. Your expert brings their own expertise and judgment to the work: the structure, the emphasis, which angles they dig into, and how they organize their findings will all vary based on your industry, your specific question, and where the research leads. What stays consistent across every engagement is the standard: analysis grounded in evidence, prioritized recommendations, concrete action steps, and a phased implementation plan. All company names, figures, and scenarios in this sample are illustrative.

How to Use This Document

This narrative deck serves two purposes simultaneously:

1. If pursuing PE partnership: It is the foundation for the management presentation — the story Meridian's leadership team tells in partner meetings about who they are, why the market is moving in their direction, and why Meridian specifically is the right platform investment in the Carolinas.

2. If choosing independent growth: It is the internal strategic clarity document — the shared understanding of what Meridian is building toward and why, which every location leader, clinical director, and hiring manager can internalize and act on.

The strategic analysis does not change between scenarios. Only the audience and some of the framing do.

Slide 1: The Situation

Meridian Physical Therapy Group operates 14 outpatient physical therapy clinics across North and South Carolina, with:

• $22.4M in trailing twelve-month (TTM) revenue
• $3.8M EBITDA (17.0% margin) — above the MSO/PE-backed platform average of 14–15%
• 188 full-time clinical staff (86 licensed PTs, 42 PTAs, 60 support staff)
• Average clinic volume: 1,340 patient visits per month per location (best-in-class for independent operators; national average is ~980)
• Physician referral network: 214 active referring providers across orthopedics, sports medicine, neurology, and primary care
• Payer mix: 61% commercial insurance, 28% Medicare, 7% Workers' Comp, 4% self-pay

The question before Meridian's leadership: Given 14 locations, $22.4M revenue, and strong clinical fundamentals, is the next phase of growth better achieved with private equity capital — or by remaining independent and executing an organic multi-state expansion?

This is not a distress decision. Meridian is profitable, growing at 11% annually, and has no debt covenant pressure. This is a choice between two fundamentally different growth architectures.

Slide 2: The Market — Why This Moment Matters

Physical therapy is consolidating rapidly, and the window for founders to set the terms is narrow.

The outpatient physical therapy market in the U.S. generates approximately $47B in annual revenue. It is highly fragmented — the top 10 platforms (ATI, U.S. Physical Therapy, Select Medical, Upstream Rehab, NovaCare, Athletico, BenchMark, Confluent Health, Phoenix PT, Concentra) control roughly 30% of the market collectively. The remaining 70% is independent operators.

That fragmentation is shrinking fast:

• PE investment in PT hit a record in 2024–2025, with over 60 platform acquisitions and add-on transactions completed in 24 months
• EBITDA multiples for well-run platforms (10+ locations, above-market margins, physician referral density) have ranged from 7.5x to 10x over the past 36 months — elevated but still rational given the recurring revenue characteristics of PT
• Staffing arbitrage: PE-backed platforms can offer PTs sign-on bonuses, loan forgiveness, and equity participation that independent operators struggle to match — creating a structural talent competition disadvantage for independents over time
• Rate environment: CMS has cut Medicare PT rates 4 consecutive years. Independent operators absorb these cuts directly; platform operators spread them across higher commercial contract negotiating leverage

The Carolinas specifically: no dominant PE-backed platform has achieved critical mass in the Raleigh-Durham, Charlotte, or Columbia MSAs. The three nearest platform players (Upstream Rehab in Charlotte perimeter, ATI in coastal SC, Confluent Health in Nashville/Knoxville approaching from the west) have not built the physician referral density that Meridian has in its core geographies. Meridian is the platform to beat in this market — or to become.

Slide 3: What Meridian Has Built

The numbers matter. The architecture behind them matters more.

Most PT groups at Meridian's revenue scale were built by opening clinics. Meridian was built by building a referral system.

The Physician Network Engine:
Meridian's 214 active referring providers represent approximately 11 years of relationship investment by founder and CEO Dr. Patricia Garland and her clinical leadership team. These are not directory referrals — they are relationships built through joint case management, outcome data sharing, co-marketing to patients, and in many cases personal friendships between Meridian PTs and orthopedic surgeons.

The consequence: Meridian's patient acquisition cost is $31 (industry average among PE-backed platforms: $68–$95). This is not a marketing efficiency — it is a structural advantage embedded in clinical relationships that would take a competitor 5–7 years to replicate.

Clinical Outcome Performance:
- Functional Outcome Measures (FOTO): Meridian clinics score in the 83rd percentile nationally on functional improvement metrics across all diagnosis groups
- Average episode length: 8.2 visits (vs. industry average 9.7 visits) — suggesting efficient care that closes faster, not undertreated patients
- Patient satisfaction (Press Ganey): 4.74/5.0 average across 14 locations
- Referral loyalty rate: 91% of Meridian's top 50 referring providers have sent patients exclusively or predominantly to Meridian for 3+ consecutive years

Operational Discipline:
- Average clinic EBITDA margin: 17.0% vs. industry average of 13–15% for platforms of comparable size
- Revenue per PT per day: $1,240 (vs. U.S. Physical Therapy's disclosed rate of ~$1,080)
- Denial rate on insurance claims: 3.2% (industry average: 6–9%)
- Payer contract renegotiation: Meridian has successfully renegotiated commercial contracts with 4 of its top 6 payers in the past 18 months, averaging a 6.3% rate increase

Slide 4: The Two Paths

Path A: PE Partnership

What it looks like: Meridian sells a majority stake (typically 60–75%) to a private equity firm, receives a substantial liquidity event ($15–22M to the founders depending on EBITDA multiple and structure), retains an equity rollover position (25–40% of the new platform entity), and becomes the management team for a regional growth platform that adds 8–15 locations per year through acquisitions and de novos.

Why it's compelling:
- Immediate liquidity — founder wealth diversification without waiting for a sale event that is years away
- Capital for growth — PE sponsors provide acquisition capital and de novo development funding that Meridian cannot self-fund at scale without taking on debt
- Infrastructure — PE platforms bring centralized billing, HR, credentialing, marketing, and revenue cycle management that free clinical leadership to focus on care
- Talent advantages — Stock options, loan forgiveness programs, and sign-on bonus budgets that improve PT recruitment in a tight labor market
- Second bite of the apple — If the platform is built and sold in 5–7 years at a higher EBITDA multiple, the rollover equity may return 3–5x on the amount retained

The risks:
- Cultural dilution — PE-backed operators frequently standardize processes and reduce clinical director autonomy to achieve operational leverage. Meridian's referral engine is relationship-based; it depends on clinicians who feel like owners, not employees.
- Multiple compression risk — The PT sector has seen EBITDA multiple compression from peak levels. A sponsor buying at 8x and needing to exit at 6.5x creates real pressure to cut costs or grow revenue through volume, not quality.
- Timeline mismatch — PE investment horizons are typically 4–7 years. Meridian's physician relationships are built on the assumption that Dr. Garland and the clinical leadership team are long-term partners. A sale event within 5 years could damage those relationships.
- Earn-out risk — Many PE deals include earn-out provisions tied to EBITDA growth. If market conditions deteriorate (additional Medicare cuts, staffing cost inflation), founders may leave significant money on the table.

Realistic valuation range: At 7.5x–9.0x TTM EBITDA of $3.8M, Meridian's enterprise value is $28.5M–$34.2M. Assuming a 65% stake sale at 8.5x, founders receive approximately $21M upfront plus a rollover stake worth $10–12M at current value.

Path B: Independent Growth

What it looks like: Meridian retains 100% ownership, uses operating cash flow and a modest bank credit facility (likely $4–6M) to open 4–6 de novo clinics over 36 months, continues to build physician relationships and payer leverage, and positions for a strategic sale or PE transaction in 4–5 years at a meaningfully higher revenue and EBITDA base.

Why it's compelling:
- Preserve culture — Meridian's referral engine and clinical outcomes are directly dependent on clinical director autonomy and the relationship capital Dr. Garland has built. Independent growth protects both.
- Higher future valuation — A platform with 20–22 locations and $30M+ revenue commands stronger multiples and more PE sponsor interest than a 14-location operator. The 36-month delay may be worth $5–10M in additional founder proceeds.
- Relationship integrity — Referring physicians have told Meridian's leadership team directly that they "send patients to Meridian because it's Patricia's practice." A PE event is a relationship signal that can shift referral behavior.
- Operational control — Independent operators can respond faster to local market conditions, clinical staffing needs, and payer negotiations without approval chains.

The risks:
- Talent competition intensifies — Without PE capital behind sign-on bonuses and equity programs, Meridian competes for licensed PTs against platforms with deeper pockets. This is the most significant operational risk of independence in the current labor market.
- Medicare rate environment — Additional CMS cuts (projected -2.3% for 2027) will compress margins. A larger commercial payer base (achievable with more locations in suburban growth corridors) provides a hedge; independence slows that geographic diversification.
- Execution risk on de novos — Meridian has opened 3 de novo clinics in the past 4 years, with mixed results (one underperformed for 18 months before reaching target volume). Scaling de novo production to 2 per year with existing management bandwidth is achievable but not risk-free.
- Window risk — PE multiples are cyclical. The current 7.5–9x range has been elevated by historically low interest rates and high deal flow. If rates remain elevated through 2027–2028, multiples may compress to 6–7x, reducing the value of waiting.

Projected valuation at exit in 3–4 years (base case): 20 locations, $30M revenue, $5.1M EBITDA → at 8x EBITDA, enterprise value of $40.8M. Founders retain 100% → gross proceeds $40.8M (vs. ~$31M in total value from Path A at current terms). Net of time value and opportunity cost, the gap narrows but Path B is modestly higher in the base case.

Slide 5: The Decision Framework

The honest summary: Path A is the right choice if Dr. Garland and the leadership team are ready to move from builders to operators-within-a-platform, want liquidity now, and believe the right PE partner can be found. Path B is the right choice if the team is energized by another 4–5 years of independent building, is confident it can win the talent competition, and believes waiting produces meaningfully higher total proceeds.

Neither path is wrong. They optimize for different outcomes.

Slide 6: If PE — What Makes a Good Partner

Not all PE sponsors are equivalent. Meridian should evaluate any potential sponsor on:

1. Healthcare services operational experience — specifically outpatient rehabilitation, not just healthcare broadly. Sponsors who understand payer dynamics, CMS rate cycles, and clinical staffing will be meaningfully better stewards than generalist healthcare investors.

2. Existing portfolio conflicts — Does the sponsor have a competing PT platform in the Carolinas? If so, this is likely an add-on acquisition rather than a platform investment — different deal structure, different management role, less autonomy.

3. Management team retention record — Ask to speak with the founders of their last 3 platform acquisitions. Are they still in seat? Have any left before the exit? Founder departure post-acquisition is the single clearest signal of cultural misalignment.

4. Capital commitment to de novos vs. acquisitions — Meridian's organic growth capability (the referral engine) is best leveraged through de novo clinics, not tuck-in acquisitions. A sponsor who insists on an acquisition-heavy growth strategy is undervaluing Meridian's actual competitive advantage.

5. Earn-out structure — Insist on EBITDA-based earn-outs that exclude uncontrollable variables (CMS rate cuts, COVID-type events). Revenue-based earn-outs in a declining-rate environment are a trap.

Target sponsor profile: Mid-market PE firms ($500M–$2B AUM) with a dedicated healthcare services practice and at least one existing outpatient rehab platform investment. Logical candidates to explore: Shore Capital Partners, Thurston Group, BBCP, Kinderhook Industries, Great Point Partners.

Slide 7: If Independent — The 36-Month Roadmap

At this pace, Meridian reaches 18 locations and approximately $28M revenue by end of FY2028, with projected EBITDA of $4.6M — supporting a $34–41M enterprise value at exit.

Recommendations

1. Make the fundamental decision before engaging any external parties. The management team must align internally on which path they are pursuing before speaking with bankers, PE sponsors, or lenders. Engaging a sell-side process "just to see" without genuine intent is corrosive to management focus and sends market signals Meridian may not want to send. Hold a full leadership team offsite to reach genuine consensus — not a vote, but a real conversation about what the team wants.

2. If pursuing PE: mandate a competitive process with at least 4–5 qualified sponsors. The difference between a 7.5x and a 9.0x multiple on Meridian's EBITDA is approximately $5.7M in proceeds. That spread is only achievable through genuine competition. Engage a healthcare-focused investment banker (Provident Healthcare Partners, Brentwood Capital Advisors, or Juniper Advisory are appropriate for this transaction size) to run a structured process with 4–5 qualified sponsors simultaneously.

3. If pursuing independence: immediately address the talent competition gap with a phantom equity program. The single biggest structural risk of independence is the inability to offer PT candidates equity-like compensation. A well-designed phantom equity or profit interest program — where licensed PTs and clinical directors vest into a percentage of clinic-level or company-level economic value — is the most direct response. This can be designed and implemented in 60–90 days for less than $100K in legal and administrative cost.

4. In either scenario, protect Dr. Garland's physician relationships through any transition. These relationships are Meridian's primary competitive asset. If pursuing PE, build explicit contractual protections into the transaction — including Dr. Garland's continued clinical leadership role, geographic restrictions on the sponsor from cutting physician relationship programs, and required continued investment in the referring provider network. If pursuing independence, ensure Dr. Garland has a formal succession plan for relationship continuity in the event of her reduced clinical role.

5. Commission an independent payer contract audit before either transaction. Meridian's 17% EBITDA margin is impressive but depends on contracted rates that may have room to move. An independent audit of Meridian's top 12 payer contracts vs. regional market rates could reveal $400K–$900K in incremental annual revenue — either improving the independence cash flow model or improving the PE valuation. This is a 30–60 day engagement at a cost of approximately $15K–$25K with meaningful potential upside.

6. Conduct confidential retention conversations with the top 10 clinical directors before announcing any path. These are the people who carry physician relationships, manage daily clinic operations, and retain staff. Their response to a PE announcement or an accelerated growth plan will determine execution quality. Know their sentiment before making a public decision — and address concerns proactively, not reactively.

Action Steps

Implementation Plan

Phase 1: Decision & Preparation (January – March 2027)

Objective: Achieve genuine internal alignment on path, complete foundational diligence work, and position Meridian to move quickly once a path is chosen.

Outputs / Milestones:
- Leadership offsite completed; path decision made with full team consensus
- Payer contract audit commissioned and in progress
- Top 10 clinical director retention conversations complete
- Physician relationship documentation complete (top 20 referring providers)
- Path-specific preparation begun (banker selected OR VP Growth search launched + equity program designed)

Success Criteria:
- Leadership team aligned on path without ambiguity by March 1
- No key clinical director or leadership team departures during the decision period
- Payer audit underway with preliminary findings by March 31
- Relevant path-specific workstream initiated

Dependencies:
- CEO willingness to hold a real, facilitated leadership conversation (not a top-down announcement)
- CFO availability to lead banker selection or equity program design in parallel
- Clinical directors' availability for confidential 1:1 conversations

Phase 2: Execution (April – December 2027)

Objective (PE Path): Complete a competitive sponsor process and close a transaction on terms that protect clinical culture, physician relationships, and founder economics.

Objective (Independence Path): Open first de novo, launch equity program, and build the management infrastructure for 18+ location operation.

Outputs / Milestones (PE Path):
- CIM and data room complete (April)
- Management presentations with 4–5 sponsors (May–June)
- LOI received and selected (July)
- Due diligence and legal close (August–October)
- Transaction closed; management rollover equity structured (November)

Outputs / Milestones (Independence Path):
- VP of Growth in seat (April)
- Phantom equity program live (May)
- De novo #15 build-out complete; clinic open (July)
- Credit facility closed; de novo #16 site signed (September)
- End of year: 15 active locations, $24M+ revenue trajectory

Success Criteria (PE Path):
- Transaction at ≥ 8.0x EBITDA multiple
- Dr. Garland in CEO role post-close with defined authority over clinical operations
- All top 10 clinical directors retained through close and 12 months post-close
- Physician relationship protection provisions in definitive agreement

Success Criteria (Independence Path):
- De novo #15 open and at 50%+ target volume by December
- ≥ 8 clinical staff enrolled in phantom equity program
- Zero clinical director departures attributed to competitive offers from PE-backed platforms
- FY2028 growth plan approved by leadership team by December 31

Dependencies (Both Paths):
- Payer contract audit findings incorporated into planning
- Physician relationship documentation completed and maintained
- Key clinical director retention confirmed through Phase 1 conversations

Document owner: CEO (Dr. Patricia Garland) · Prepared in connection with Meridian leadership strategic planning process, Q1 2027 · Confidential — not for external distribution without explicit CEO approval